<DOC>
	<DOC>NCT02350218</DOC>
	<brief_summary>The purpose of this study is to evaluate superiority of Eglandin® (Alprostadil) 720㎍compared to 360㎍ in terms of safety, efficacy in living donor liver transplant patient, peak AST levels followed by Eglandin administration were assessed.</brief_summary>
	<brief_title>Safety and Efficacy Study of Eglandin in Living Donor Liver Transplant Patient</brief_title>
	<detailed_description />
	<mesh_term>Alprostadil</mesh_term>
	<criteria>1. Primary living donor liver transplantation 2. Patient received modified right lobe graft 3. Aged between 19 to 65 years 4. Informed consent 1. ABO incompatibility 2. Dual liver transplant patient from 2 donors 3. History of liver transplantation or other organ transplantation 4. Transplantation of other organ(s) at the time of liver transplantation 5. Use of artificial liver device prior to liver transplantation 6. UNOS status Ⅰor ⅡA 7. History of malignant tumor within 5 years 8. Not included in Milan liver transplant criteria for hepatocellular carcinoma 9. Patient with WBC &lt; 2,000/mm3 or ANC &lt; 900/mm3 or platelet &lt; 30,000/mm3 at the time of screening 10. Patient exposed to severe systemic infection requiring treatment 11. Positive response for HIV in either donor or recipient 12. Prior administration of other investigational product within 30 days (or 5 times the half life) from date of screening 13. Women of childbearing age without effective contraception, breast feeding and pregnant women 14. Substance abuser, patient with metal disorder, and otherwise legally not eligible patient 15. Not eligible to participate at discrete of study investigator</criteria>
	<gender>All</gender>
	<minimum_age>19 Years</minimum_age>
	<maximum_age>65 Years</maximum_age>
	<verification_date>January 2017</verification_date>
	<keyword>Transplantation</keyword>
	<keyword>Living donor</keyword>
	<keyword>Eglandin</keyword>
	<keyword>Alprostadil</keyword>
</DOC>